Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135443 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HRH3CYP2D6CYP2C19HTR2C | |
| SCHEMBL4141014 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HRH3CYP2D6CYP2C19HTR2C | |
| SCHEMBL4128005 | 0.89 | CD274 (0.50) | ALDH1A1HRH3HTR2CHTR2BDRD3 | |
| SCHEMBL4129108 | 0.87 | HRH3 (0.52) | ALDH1A1HRH3CYP2D6CYP2C19HTR2C | |
| SCHEMBL4152777 | 0.87 | ALDH1A1 (0.45) | ALDH1A1HRH3CYP11B2 | |
| SCHEMBL4141993 | 0.86 | HTR1D (0.38) | ALDH1A1HRH3CYP2D6HTR1D | |
| SCHEMBL4148823 | 0.86 | HTR2A (0.41) | ALDH1A1HRH3CYP2D6HTR2CCYP11B2 | |
| SCHEMBL4127181 | 0.85 | ALDH1A1 (0.41) | ALDH1A1HTR2CHTR2BCYP11B2DRD2 | |
| SCHEMBL4144848 | 0.85 | ALDH1A1 (0.39) | ALDH1A1HRH3CYP2D6CYP2C19HTR2C | |
| SCHEMBL4135983 | 0.85 | ALDH1A1 (0.40) | ALDH1A1HRH3HTR2CHTR2BCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | disclosed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | ALDH1A1 1667/4885HRH3 1/4885CYP2D6 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.